1 / 6

U.S. Food and Drug Administration

U.S. Food and Drug Administration. Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated. . Steven D. Vaughn, DVM. Director

latona
Download Presentation

U.S. Food and Drug Administration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

  2. Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U.S. Food & Drug Administration Rockville, MD 20855

  3. Guidance for Industry #152 • Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern • October 23, 2003

  4. Qualitative Risk Assessment • Release assessment • H, M, L • Exposure assessment • H, M, L • Consequence assessment Critically important, Highly important, Important

  5. Assessment outcomes integrated into a RISK ESTIMATION • HIGH • MEDIUM • LOW

More Related